<DOC>
	<DOCNO>NCT02201199</DOCNO>
	<brief_summary>Primary Objective : To compare pharmacokinetic ( PK ) characteristic single dos insulin glargine give U200 U500 single dose ( SD ) Lantus® U100 euglycemic clamp set subject type 1 diabetes . Secondary Objectives : To compare metabolic activity characteristic single dos insulin glargine give U200 U500 single dose Lantus® U100 euglycemic clamp set subject type 1 diabetes . To assess safety tolerability single dos U200 , U500 Lantus® U100 subject type 1 diabetes .</brief_summary>
	<brief_title>Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus</brief_title>
	<detailed_description>Total study duration subject 3.5 12 week . Two overnight stay unit 3 treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Male female subject , 18 65 year age , inclusive , type 1 diabetes mellitus one year , define American Diabetes Association . Total insulin dose &lt; 1.2 U/kg/day . Minimum usual basal insulin dose ≥0.2 U/kg/day . Body weight 50.0 kg 110.0 kg , Body Mass Index 18.5 30.0 kg/m2 inclusive . Fasting negative serum Cpeptide ( &lt; 0.3 nmol/L ) . Glycohemoglobin ( HbA1c ) ≤75 mmol/mol ( ≤9.0 % ) . Stable insulin regimen least 2 month prior inclusion study . Certified otherwise healthy Type 1 diabetes mellitus patient . Women childbearing potential negative pregnancy test use highly effective contraceptive method woman confirm postmenopausal status . Having give write informed consent prior undertake studyrelated procedure . Exclusion criterion : More one episode severe hypoglycemia seizure , coma require assistance another person past 6 month . Frequent severe headache / migraine , recurrent nausea / vomiting ( twice month ) . Presence history drug allergy clinically significant allergic disease accord Investigator 's judgment . Presence history drug alcohol abuse ( alcohol consumption &gt; 40 gram / day ) . Smoking 5 cigarette equivalent per day , unable refrain smoking . Any medication ( include St John 's Wort ) within 14 day inclusion , within 5 time elimination halflife pharmacodynamic halflife drug , whichever long regular use medication last month study start exception insulin product , thyroid hormone , lipidlowering antihypertensive drug , , female , exception hormonal contraception menopausal hormone replacement therapy ; vaccination within last 28 day ; biologics ( antibody derivative ) give within 4 month randomization . Known hypersensitivity insulin glargine excipients study drug . Any history presence deep leg vein thrombosis frequent appearance deep leg vein thrombosis first degree relative ( parent , sibling child ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>